Webinar: HREC & Governance

Ethics Overhaul Looms

The National Statement on Ethical Conduct in Human Research, issued by the NHMRC in collaboration with the Australian Research Council and Universities Australia, sets binding ethical standards for all human research in Australia. Compliance is mandatory for NHMRC funding and underpins the work of Human Research Ethics Committees (HRECs) that review proposals involving people.

In April 2025, the NHMRC published a revised version, fully overhauling Section 4 on ethical considerations for participants and making consequential tweaks across nearly every other section. Originally slated for effect on 1 October 2025, the implementation date was delayed in September 2025 to early 2026, giving universities, hospitals, and other institutions extra months to update internal policies, forms, training, and decision-making processes.

The most significant change reframes ethical scrutiny away from labelling certain groups as inherently 'vulnerable'—a term critics argued stigmatised participants—towards assessing actual increased risk of harm from the research itself or from participants' circumstances. This opens doors for more inclusive research by emphasising participation of under-represented groups and permits lower-risk studies involving previously mandatory HREC-reviewed populations to use expedited or alternative ethics pathways.

Real-world effects ripple through Australia's research ecosystem. HRECs, often based in public hospitals or universities, face immediate workload and training pressures; inconsistent early adoption could lead to patchy application until the firm deadline. Researchers risk delays or rejections if submissions straddle old and new rules, while institutions risk governance failures or funding ineligibility post-transition. Multi-site trials, already hampered by duplicated reviews, gain potential streamlining but only if accreditation and mutual acceptance schemes advance in tandem.

Less visible tensions include the trade-off between flexibility and protection: easing mandatory HREC oversight for some studies could speed innovation in fields like public health or rare diseases, yet some stakeholders worry it dilutes safeguards for historically disadvantaged communities. Parallel national efforts, including accreditation for HRECs and moves toward a single national ethics approval, amplify the stakes—failure to adapt swiftly could undermine Australia's attractiveness as a clinical trials destination.

The window for adjustment is narrowing, with the effective date still unconfirmed but imminent in 2026.